Heparin-coated Palmaz-Schatz stents in human coronary arteries: Early outcome of the Benestent-II pilot study

Circulation

Volumn 93, Issue 3, 1996, Pages 412-422

  Serruys, Patrick W ^a   Emanuelsson, Håkan ^a   Van Der Giessen, Wim ^a   Lunn, Anthony C ^a   Kiemeney, Ferdinand ^a   Macaya, Carlos ^a   Rutsch, Wolfgang ^a   Heyndrickx, Guy ^a   Suryapranata, Harry ^a   Legrand, Victor ^a   Goy, Jean Jacques ^a   Materne, Pierre ^a   Bonnier, Hans ^a   Morice, Marie Claude ^a   Fajadet, Jean ^a   Belardi, Jorge ^a   Colombo, Antonio ^a   Garcia, Eulogio ^a   Ruygrok, Peter ^a   De Jaegere, Peter ^a   Morel, Marie Angèle ^a   more..

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

angina; anticoagulants; coating; heparin; stents

Indexed keywords

ACETYLSALICYLIC ACID; HEPARIN; TICLOPIDINE; WARFARIN;

ADULT; ANGINA PECTORIS; ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FOLLOW UP; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; PATIENT SELECTION; PHASE 4 CLINICAL TRIAL; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; STENT; SURGICAL APPROACH; SURGICAL TECHNIQUE; SURVIVAL RATE; THROMBOSIS;

EID: 9044251603     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.93.3.412     Document Type: Article

References (46)

1. Serruys PW, Beatt KJ, Van der Giessen WJ. Stenting of coronary arteries: are we the sorcerer's apprentice? Eur Heart J. 1989;10: 774-782.
2. Serruys PW, Strauss BH, Van Beusekom HMM, van der Giessen WJ Stenting of coronary arteries: has a modern Pandora's box been opened? J Am Coll Cardiol. 1991;17:143B-154B.
3. Serruys PW, De Jaegere P, Kiemenij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P, Belardi J, Sigwart U, Colombo A, Goy J, van den Heuvel P, Delcan J, Morel M. A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 1994;331:489-495.
4. Serruys PW, Di Mario C. Who was thrombogenic: the stent or the doctor? Circulation. 1995;91:1891-1893.
5. Bailey SR, Paige S, Lunn AC, Palmaz J. Heparin coating of endovascular stents decreases subacute thrombosis in a rabbit model. Circulation. 1992;86(suppl I):I-186. Abstract.
6. Stratienko AA, Zhu D, Lambert CR, Palmaz J, Schatz RA, Santamore WP. Improved thromboresistance of heparin-coated Palmaz-Schatz coronary stents in an animal model. Circulation. 1993;88(Pt 2):I-596. Abstract.
7. Emanuelsson H, Van der Giessen WJ, Serruys PW. Benestent II: back to the future. J Interven Cardiol. 1994;7:587-592.
8. Hårdhammer PA, Van Beusekom H, Emanuelsson HV, Hofma SH, Albertsson PA, Verdouw PD, Boersma E, Serruys PW, Van der Giessen WJ. Reduction of thrombotic events using heparin-coated Palmaz-Schatz stents in normal porcine coronary arteries. Circulation. 1996;93:423-430.
9. Blackburn H, Keys A, Simonson E, Rautaharju P, Punsars R. The electrocardiogram in population studies: a classification system. Circulation. 1960;21:1160-1175.
10. Hoffman AS, Schmer G, Harris C, Kraft WG. Covalent bonding of biomolecules to radiografted hydrogels on inert polymer surfaces. Trans Am Soc Artif Intern Organs. 1972;18:10-16.
11. Larm O, Larsson R, Olsson P. Surface-immobilized heparin. In: Lane DA, Lindahl U, eds. Heparin: Chemical and Biological Properties, Clinical Applications. London, UK: Edward Arnold Press; 1989;99:597-608.
12. Serruys PW, Foley DP, De Feyter PJ, eds. Quantitative Coronary Angiography in Clinical Practice. Dordrecht, the Netherlands: Kluwer Academic; 1994.
13. Greenland S, Robins JM. Estimation of a common effect parameter from sparse follow-up data. Biometrics. 1985;41:55-68.
14. Hastings GW. ed. Cardiovascular Biomaterials. London, UK: Springer-Verlag; 1992.
15. Eloy R, Belleville J. Biomaterial-blood interaction. In: Williams D, ed. Concise Encyclopedia of Medical and Dental Materials. Elmsford, NY: Pergamon Press; 1990:74-85.
16. Marcum JA, Rosenberg RD. Heparin-like molecules with anticoagulant activity are synthesized by cultured endothelial cells. Biochem Biophys Res Commun. 1985;126:365-372.
17. Awbrey B, Hoak JC, Owen WG. Binding of human thrombin to cultured human endothelial cells. J Biol Chem. 1979;254:4092-4095.
18. Lelah MD, Lambracht LK, Cooper SL. A canine ex vivo series shunt experiment for evaluating thrombus deposition on polymer surfaces. J Biomed Mater Res. 1984;18:475-496.
19. Von Segesser LK, Turina M. Cardiopulmonary bypass without systemic heparinization. J Thorac Cardiovasc Surg. 1989;98:386-396.
20. Palanzo DA, Kurusz M, Butler BD. Surface tension effects of heparin coating on arterial line filters. Perfusion. 1990;5:277-284.
21. Taylor KM, Von Segesser LK, Weiss BM, Gallino A, Leskosek B, Redha F, Von Felten A, Turina M. Superior hemodynamics in left heart bypass without systemic heparinization. Eur J Cardiothorac Surg. 1990;4:384-389.
22. Hsu L-C. Principles of heparin-coating techniques. Perfusion. 1991; 6:209-219.
23. Lindahl U, Bäckström G, Höök M, Thunberg L, Linker A. Structure of the antithrombin-binding site in heparin. Proc Natl Acad Sci USA. 1979;76:3198-3202.
24. Thunberg L, Bäckström G, Lindahl U. Further characterization of the antithrombin-binding sequence in heparin. Carbohydr Res. 1982;100:393-410.
25. Pratt CW, Church FC. Antithrombin: structure and function. Semin Hematol. 1991;28:3-9.
26. Breckwoldt WL, Belkin M, Gould K, Allen M, Connoly RJ, Termin P. Modification of the thrombogenicity of a self-expanding vascular stem. J Invest Surg. 1991;4:269-278.
27. Grode GA, Anderson SJ, Grotta HM, Falb RDD. Nonthrombogenic material via a simple coating process. Trans Am Soc Artif Intern Organs. 1969;15:1-5.
28. Tanzawa H, Mori Y, Harumiyua N, Miyama H, Hori M. Preparation and evaluation of a new antithromhogenic heparinized hydrophyllic polymer for use in cardiovascular systems. Trans Am Soc Artif Intern Organs. 1973;19:1888-1894.
29. Jozefowicz M, Jozefowicz J. Heparin-containing and heparin-like polymers. In: Chiellini E, Giusti P, eds. Polymers in Medicine. New York, NY: Plenum Press; 1983.
30. Labarre D, Boffa MC, Jozefowicz M. Properties of heparin-poly(metyl methacrylate)copolymer. J Biomed Mater Res. 1977;11: 283-295.
31. Miyama H, Harumiya N, Mori Y, Tanzawa H. A new antithrombogenic heparinized polymer. J Biomed Res. 1977;11:251-265.
32. Heyman PW, Cho CS, McRea JC, Olsen DB, Kim SW. Heparinized polyurethanes: in vitro and in vivo studies. J Biomed Mater Res. 1985;19:419-436.
33. Larm O, Larsson R, Olsson P. A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue. Biomater Med Devices Artif Organs. 1983; 11:161-173.
34. Hoffman J, Larm O, Scholander E. A new method for covalent coupling of heparin and other glycosaminoglycans to substances containing primary amino groups. Carbohdyr Res. 1983;117: 328-331.
35. Salzman EW, Rosenberg RDS, Smith MH, Lindon JH, Favrean L. Effect of heparin and heparin fragments on platelet aggregation. J Clin Invest. 1980;65:64-73.
36. Larsson R, Larm O, Olsson P. The search for thromboresistance using immobilized heparin. Ann NY Acad Sci. 1987;516:102-115.
37. Barragan P, Sainsous J, Silvestri M, Bouvier JL, Cornet B, Siméoni JB, Charmasson C, Brcmondy M. Ticlopidin and subcutaneous heparin as an alternative regimen following coronary stenting. Cathet Cardiovasc Diagn. 1994;31:133-138.
38. Morice MC, Zemour G, Benveniste E, Biron Y, Bourdonnec C, Faivre R, Fajadet J, Gaspard P, Glatt B, Joly P, Labrunie P, Lienhart Y, Marco J, Petiteau PY, Royer T, Valeix B. Intracoronary stenting without coumadin: one month results of a French multicenter study. Cathet Cardiovasc Diagn. 1995;35:1-7.
39. Colombo A, Hall P, Nakamura S, Almagor Y, Maiello L, Martini G, Gaglione A, Goldberg SL, Tobis JM. Intravascular stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation. 1995;91:1676-1688.
40. Hass WK, Easton JD. Ticlopidine, Platelets and Vascular Disease. New York, NY: Springer-Verlag; 1993.
41. Gawaz M, Neumann F, Ott I, May A, Schömig A. Platelet activation and coronary stent implantation: effect of antithrombotic therapy. Circulation. In press.
42. Gregorini L, Marco J, Fajadet J, Brunnel P, Cassagneau B, Bossi I. Ticlopidine attenuates post-angioplasty thrombin generation. Circulation. 1995;92(suppl I):I-608. Abstract.
43. Foley DP, Melkert R, Serruys PW. Influence of coronary vessel size on renarrowing process and late angiographic outcome after successful balloon angioplasty. Circulation. 1994;90:1239-1251.
44. Palmaz-Schatz balloon-expandable stent and delivery system: PMA 900043 Panel Package: Circulatory System Devices Panel: May 3, 1994: Division of Cardiovascular, Respiratory and Neurológical Devices: US Food and Drug Administration.
45. Lincoff AM, Van der Giessen WJ, Schwarz RS, Van Beusekom HMM, Serruys PW, Holmes DR, Ellis SG, Topol EJ. Biodegradable and biostable polymers may both cause vigorous inflammatory responses when implanted in the porcine coronary artery. J Am Coll Cardiol. 1993;21(suppl A):179A. Abstract.
46. Ambrose JA, Winters SL, Stern A, Eng A, Teichholz LE, Gorlin R, Fuster V. Angiographic morphology and the pathogenesis of unstable angina pectoris. J Am Coll Cardiol. 1985;5:609-616.